Results 1 to 10 of about 87,574 (284)

Subcutaneous immunoglobulin-induced eczematous dermatitis [PDF]

JAAD Case Reports
Rachel Breidbart, BS, Matthew D. Vesely, MD, PhD   +1 more
doaj   +4 more sources

A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases [PDF]

Allergy, Asthma & Clinical Immunology, 2022
Immunoglobulin replacement therapy is the standard-of-care treatment for patients with primary immunodeficiency diseases who have impaired antibody production and function.
Kristin Epland, Daniel Suez, Kenneth Paris   +2 more
doaj   +2 more sources

Patient-reported outcomes with subcutaneous immunoglobulin in secondary immunodeficiency [PDF]

Frontiers in Immunology
Subcutaneous (SCIG) and intravenous immunoglobulin (IVIG) replacement are both used to prevent infections in patients with secondary immunodeficiency (SID).
Juthaporn Cowan, Juthaporn Cowan, Juthaporn Cowan, Il-Kang Na, Il-Kang Na, Il-Kang Na, Il-Kang Na, André Gladiator, Marta Kamieniak, S. Shahzad Mustafa, S. Shahzad Mustafa   +10 more
doaj   +2 more sources

Cutaquig^® Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products [PDF]

Hematology Reports, 2022
Objective: Subcutaneous immunoglobulin (SCIG) treatment is generally tolerable, but some patients may experience adverse events to one or more SCIG products.
Sydney Brownlee, Crystal Allen, Mohammed F. Kana’an, D. William Cameron, Juthaporn Cowan   +4 more
doaj   +2 more sources

Рrospective multicenter study of treatment efficacy, safety, and quality of life in a large cohort of patients with inborn errors of immunity receiving subcutaneous immunoglobulin by the rapid push method [PDF]

Frontiers in Immunology
Subcutaneous immunoglobulin (SCIG) preparations are widely used in patients with inborn errors of immunity (IEI), with proven efficacy and good tolerance.
Asmik Avedova, Elena Deripapa, Yulia Rodina, Anna Mukhina, Elena Latysheva, Daria Yukhacheva, Vasily Burlakov, Nellie Kan, Daria Bogdanova, Anna Moiseeva, Natalia Kuzmenko, Zoya Nesterenko, Ekaterina Deordieva, Anna Ogneva, Victoria Bludova, Anna Roppelt, Daria Fomina, Natalia Zinovieva, Yulia Sevostyanova, Linara Kalmeteva, Dilara Prolygina, Lyudmila Barycheva, Olga Selezneva, Natalya Shakhova, Olga Laba, Elena Vlasova, Alla Gorenkova, Elena Timofeeva, Olga Trusova, Marina Guseva, Natalya Yudina, Evgeniya Grevtseva, Asya Ibisheva, Zema Bambaeva, Dina Mashkovskaya, Svetlana Isakova, Almazia Shakirova, Ekaterina Selina, Tatyana Shilova, Elena Zubova, Iman Khabaeva, Ekaterina Kitova, Anastasia Mandzhieva, Svetlana Starikova, Tatyana Pavlova, Elvira Tyulyakova, Pavel Levin, Nikolay Grachev, Anna Shcherbina   +48 more
doaj   +2 more sources

A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency [PDF]

Current Oncology, 2022
Secondary antibody deficiency (SAD) is a common complication in chronic lymphocytic leukemia (CLL) which favors the development of life-threatening infections.
Andrea Visentin, Maria Chiara Molinari, Stefano Pravato, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavaretta, Valeria Ruocco, Silvia Imbergamo, Francesco Piazza, Giulia Proietti, Francesca Romana Mauro, Livio Trentin   +11 more
doaj   +2 more sources

Infectious outcomes of a standardized subcutaneous immunoglobulin dose reduction strategy in primary immune deficiencies amid global shortage [PDF]

Frontiers in Immunology
IntroductionImmunoglobulin replacement therapy (IgRT), either intravenous (IVIg) or subcutaneous (SCIg), is crucial for managing primary immune deficiencies (PIDs) with hypogammaglobulinemia by reducing infection rates and mortality.
Pedro Moral Moral, Pedro Moral Moral, Marta Dafne Cabanero-Navalon, Marta Dafne Cabanero-Navalon, Paula Teresa López-León, Paula Teresa López-León, Héctor Balastegui-Martín, Héctor Balastegui-Martín, Sandra Martínez Mercader, Sandra Martínez Mercader, Amparo Mir, Victor Garcia-Bustos, Victor Garcia-Bustos, Victor Garcia-Bustos   +13 more
doaj   +2 more sources

Switch from Intravenous to Subcutaneous Immunoglobulin in CIDP and MMN: 12 Months Results from an Observational Study [PDF]

Neurology and Therapy
Introduction Since 2018 subcutaneous immunoglobulin (SCIg) has been approved for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
Stefan Gingele, Anna Christina Saparilla Pietschmann, Konstantin F. Jendretzky, Moritz Koch, Gudrun M. Körner, Janna M. Siemer, Franz Felix Konen, Martin W. Hümmert, Friederike Salge, Jarle von Hörsten, Tabea Seeliger, Sonja Körner, Thomas Skripuletz   +12 more
doaj   +2 more sources

Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin [PDF]

Therapeutic Advances in Neurological Disorders, 2017
K
Edina Kovács, Katalin Dankó, Melinda Nagy-Vince, László Csiba, Judit Boczán   +4 more
doaj   +2 more sources

High-dose immunoglobulin-dependent chronic inflammatory demyelinating polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis

eNeurologicalSci, 2022
Immunoglobulin G therapy for chronic inflammatory demyelinating polyneuropathy (CIDP) often requires individual dose adjustments because of the heterogeneity of pathogenesis and varying catabolic rates.
Satomi Hiya, Satoru Fujiwara, Fumiaki Tanaka, Nobuo Kohara, Michi Kawamoto   +4 more
doaj   +1 more source